View Post

What You Need to Know About the FDA’s Approval of Tukysa for HER2-Positive Breast Cancer

In In The News by Barbara Jacoby

By: Beth Fand Incollingo and Kristi Rosa From: By approving Tukysa (tucatinib) for use with the targeted drug Herceptin (trastuzumab) and the chemotherapy Xeloda (capecitabine), the Food and Drug Administration has provided a meaningful option to heavily pretreated patients with inoperable, locally advanced or metastatic HER2-positive breast cancer, including those with brain metastases, according to Dr. Rashmi Murthy. This …